Study of how cells interact to predict drug response in stomach cancer
Part of Cancer clinical trials.
This trial collects tissue samples to study why some stomach cancers become resistant to treatment. It aims to better understand how tumors and their surroundings interact, which could help doctors choose the right therapy for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stomach or gastroesophageal junction cancer that has been confirmed by biopsy.
- Your cancer must be locally advanced (spread nearby but not to distant organs) and can be surgically removed.
- You are scheduled to receive a specific chemotherapy combination called FLOT along with the immunotherapy durvalumab before surgery.
- You are 18 years old or older.
- You are willing and able to provide written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial looks at how medicines given around the time of stomach cancer surgery may change the “tumor microenvironment,” which is the biology around the tumor. It may help doctors better understand which perioperative treatments work best for locally advanced, operable stomach cancer.
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.